144 related articles for article (PubMed ID: 31753697)
21. Water-soluble prodrugs of paclitaxel containing self-immolative disulfide linkers.
Gund M; Khanna A; Dubash N; Damre A; Singh KS; Satyam A
Bioorg Med Chem Lett; 2015 Jan; 25(1):122-7. PubMed ID: 25466201
[TBL] [Abstract][Full Text] [Related]
22. Gambogic acid down-regulates MDM2 oncogene and induces p21(Waf1/CIP1) expression independent of p53.
Rong JJ; Hu R; Qi Q; Gu HY; Zhao Q; Wang J; Mu R; You QD; Guo QL
Cancer Lett; 2009 Oct; 284(1):102-12. PubMed ID: 19428175
[TBL] [Abstract][Full Text] [Related]
23.
Al-Ghabkari A; Narendran A
Cancer Biother Radiopharm; 2019 May; 34(4):252-257. PubMed ID: 30724592
[No Abstract] [Full Text] [Related]
24. Isoindolinone inhibitors of the murine double minute 2 (MDM2)-p53 protein-protein interaction: structure-activity studies leading to improved potency.
Hardcastle IR; Liu J; Valeur E; Watson A; Ahmed SU; Blackburn TJ; Bennaceur K; Clegg W; Drummond C; Endicott JA; Golding BT; Griffin RJ; Gruber J; Haggerty K; Harrington RW; Hutton C; Kemp S; Lu X; McDonnell JM; Newell DR; Noble ME; Payne SL; Revill CH; Riedinger C; Xu Q; Lunec J
J Med Chem; 2011 Mar; 54(5):1233-43. PubMed ID: 21314128
[TBL] [Abstract][Full Text] [Related]
25. Synthesis and antimycobacterial activity of prodrugs of indeno[2,1-c]quinoline derivatives.
Upadhayaya RS; Shinde PD; Kadam SA; Bawane AN; Sayyed AY; Kardile RA; Gitay PN; Lahore SV; Dixit SS; Földesi A; Chattopadhyaya J
Eur J Med Chem; 2011 Apr; 46(4):1306-24. PubMed ID: 21334792
[TBL] [Abstract][Full Text] [Related]
26. New water-soluble prodrugs of HIV protease inhibitors based on O-->N intramolecular acyl migration.
Hamada Y; Ohtake J; Sohma Y; Kimura T; Hayashi Y; Kiso Y
Bioorg Med Chem; 2002 Dec; 10(12):4155-67. PubMed ID: 12413869
[TBL] [Abstract][Full Text] [Related]
27. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
[TBL] [Abstract][Full Text] [Related]
28. HIPK2 regulation by MDM2 determines tumor cell response to the p53-reactivating drugs nutlin-3 and RITA.
Rinaldo C; Prodosmo A; Siepi F; Moncada A; Sacchi A; Selivanova G; Soddu S
Cancer Res; 2009 Aug; 69(15):6241-8. PubMed ID: 19638586
[TBL] [Abstract][Full Text] [Related]
29. Mdm2 Splice isoforms regulate the p53/Mdm2/Mdm4 regulatory circuit via RING domain-mediated ubiquitination of p53 and Mdm4.
Fan C; Wang X
Cell Cycle; 2017 Apr; 16(7):660-664. PubMed ID: 28166445
[TBL] [Abstract][Full Text] [Related]
30. p53-Mdm2 Interaction Inhibitors as Novel Nongenotoxic Anticancer Agents.
Nayak SK; Khatik GL; Narang R; Monga V; Chopra HK
Curr Cancer Drug Targets; 2018; 18(8):749-772. PubMed ID: 28669344
[TBL] [Abstract][Full Text] [Related]
31. Gambogic acid mediates apoptosis as a p53 inducer through down-regulation of mdm2 in wild-type p53-expressing cancer cells.
Gu H; Wang X; Rao S; Wang J; Zhao J; Ren FL; Mu R; Yang Y; Qi Q; Liu W; Lu N; Ling H; You Q; Guo Q
Mol Cancer Ther; 2008 Oct; 7(10):3298-305. PubMed ID: 18852133
[TBL] [Abstract][Full Text] [Related]
32. Enhanced cytotoxicity of prenylated chalcone against tumour cells via disruption of the p53-MDM2 interaction.
Leão M; Soares J; Gomes S; Raimundo L; Ramos H; Bessa C; Queiroz G; Domingos S; Pinto M; Inga A; Cidade H; Saraiva L
Life Sci; 2015 Dec; 142():60-5. PubMed ID: 26475964
[TBL] [Abstract][Full Text] [Related]
33. A mouse p53 mutant lacking the proline-rich domain rescues Mdm4 deficiency and provides insight into the Mdm2-Mdm4-p53 regulatory network.
Toledo F; Krummel KA; Lee CJ; Liu CW; Rodewald LW; Tang M; Wahl GM
Cancer Cell; 2006 Apr; 9(4):273-85. PubMed ID: 16616333
[TBL] [Abstract][Full Text] [Related]
34. MDM2 but not MDM4 promotes retinoblastoma cell proliferation through p53-independent regulation of MYCN translation.
Qi DL; Cobrinik D
Oncogene; 2017 Mar; 36(13):1760-1769. PubMed ID: 27748758
[TBL] [Abstract][Full Text] [Related]
35. Tetra-substituted imidazoles as a new class of inhibitors of the p53-MDM2 interaction.
Vaupel A; Bold G; De Pover A; Stachyra-Valat T; Lisztwan JH; Kallen J; Masuya K; Furet P
Bioorg Med Chem Lett; 2014 May; 24(9):2110-4. PubMed ID: 24704029
[TBL] [Abstract][Full Text] [Related]
36. Design, synthesis, and biological evaluation of imidazoline derivatives as p53-MDM2 binding inhibitors.
Hu C; Li X; Wang W; Zhang L; Tao L; Dong X; Sheng R; Yang B; Hu Y
Bioorg Med Chem; 2011 Sep; 19(18):5454-61. PubMed ID: 21855354
[TBL] [Abstract][Full Text] [Related]
37. Benzimidazoles Downregulate Mdm2 and MdmX and Activate p53 in MdmX Overexpressing Tumor Cells.
Mrkvová Z; Uldrijan S; Pombinho A; Bartůněk P; Slaninová I
Molecules; 2019 Jun; 24(11):. PubMed ID: 31181622
[TBL] [Abstract][Full Text] [Related]
38. Combination of amino acid/dipeptide with nitric oxide donating oleanolic acid derivatives as PepT1 targeting antitumor prodrugs.
Fang L; Wang M; Gou S; Liu X; Zhang H; Cao F
J Med Chem; 2014 Feb; 57(3):1116-20. PubMed ID: 24422538
[TBL] [Abstract][Full Text] [Related]
39. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction.
Allen JG; Bourbeau MP; Wohlhieter GE; Bartberger MD; Michelsen K; Hungate R; Gadwood RC; Gaston RD; Evans B; Mann LW; Matison ME; Schneider S; Huang X; Yu D; Andrews PS; Reichelt A; Long AM; Yakowec P; Yang EY; Lee TA; Oliner JD
J Med Chem; 2009 Nov; 52(22):7044-53. PubMed ID: 19856920
[TBL] [Abstract][Full Text] [Related]
40. Oxazoloisoindolinones with in vitro antitumor activity selectively activate a p53-pathway through potential inhibition of the p53-MDM2 interaction.
Soares J; Pereira NA; Monteiro Â; Leão M; Bessa C; Dos Santos DJ; Raimundo L; Queiroz G; Bisio A; Inga A; Pereira C; Santos MM; Saraiva L
Eur J Pharm Sci; 2015 Jan; 66():138-47. PubMed ID: 25312347
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
